Unconscious Reduction of Fear Through Decoded Neuro-Reinforcement
NCT06420557, Not applicable, Recruiting, University of California, Los Angeles
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Unconscious Reduction of Fear Through Decoded Neuro-Reinforcement | ClinicalTrials.gov |
| NCT number | NCT06420557 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 60 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of California, Los Angeles | ClinicalTrials.gov |
| Conditions | Phobia | ClinicalTrials.gov |
| Interventions | Unconscious Neuro-reinforcement, Unconscious Neuro-reinforcement, Unconscious Neuro-reinforcement | ClinicalTrials.gov |
| First posted | 2024-05-20 | ClinicalTrials.gov |
| Last updated | 2026-10-05 | ClinicalTrials.gov |
Registered outcomes 12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Amygdala Reactivity | 14 days (measured at pre-treatment and 2 weeks) | The neural measure of difference in amygdala reactivity (measured by fMRI) to target phobic animals compared to control phobic animals from pre-treatment to post-treatment. Lower numbers (i.e. more negative numbers) indicate greater amygdala decrease and and better outcomes. | ClinicalTrials.gov |
| Primary | Subjective Fear Post-treatment Minus Pre-treatment | 14 days (measured at pre-treatment and 2 weeks) | Subjective Fear Ratings of images of targeted phobic stimuli Minimum score of 0, Maximum score of 180, higher scores mean worse outcome. | ClinicalTrials.gov |
| Secondary | Skin Conductance Response: Physiological Arousal Post-treatment Minus Pre-treatment | 14 days (measured at pre-treatment and 2 weeks) | Skin conductance to image presentation of targeted phobic stimuli post-treatment minus pre-treatment | ClinicalTrials.gov |
| Secondary | Fear Survey Schedule | 14 days (measured at pre-treatment and 2 weeks) | Subjective fear ratings of a list of typical phobic stimuli Minimum score of 40, maximum of 200, higher scores mean worse outcome. | ClinicalTrials.gov |
| Secondary | Stroop Task Post-treatment Minus Pre-treatment | 14 days (measured at pre-treatment and 2 weeks) | Measure of preferential allocation of attentional resources measured in reaction time (seconds) for visual presentation of the targeted phobic stimulus | ClinicalTrials.gov |
| Secondary | Approach/Avoidance Behavior in VR Post-treatment Minus Pre-treatment | 14 days (measured at pre-treatment and 2 weeks) | Maximal approach distance will be assessed in a behavioral approach test conducted in a virtual reality context. The Behavioral Approach Test follows a ten-step procedure of increasing difficulty to approach a feared animal (e.g. snakes), beginning with a first step such as standing in the same room as the feared animal. Then, participants approach the feared animal step-by-step, taking time at each step, until a final step such as holding the feared animal or having it touch you is reached. Behavioral outcomes that will be measured from the Behavioral Approach Test include a) maximal approach distance and b) subjective fear ratings at each distance. Minimum score for approach distance is 1, and highest is 10 (numbers represent steps taken toward fearful stimulus). Higher scores represent a better outcome on this task. | ClinicalTrials.gov |
| Secondary | Subjective Fear Ratings in Virtual Reality (VR) Post-treatment Minus Pre-treatment | 14 days (measured at pre-treatment and 2 weeks) | Subjective fear ratings will be assessed at each distance in a behavioral approach test conducted in a virtual reality context. The Behavioral Approach Test follows a ten-step procedure of increasing difficulty to approach a feared animal (e.g. snakes), beginning with a first step such as standing in the same room as the feared animal. Then, participants approach the feared animal step-by-step, taking time at each step, until a final step such as holding the feared animal or having it touch you is reached. Minimum score for subjective fear is 1, and maximum is 8. Higher scores represent a worse outcome on this task. | ClinicalTrials.gov |
| Secondary | Patient Health Questionnaire (PHQ-9) | 14 days (measured at pre-treatment and 2 weeks) | Self-reported depression severity. Scores range from 0-27, with higher scores indicating greater severity. | ClinicalTrials.gov |
| Secondary | Generalized Anxiety Disorder-7 (GAD-7) | 14 days (measured at pre-treatment and 2 weeks) | Self-reported anxiety severity. Scores range from 0-21, with higher scores indicating greater severity. | ClinicalTrials.gov |
| Secondary | Severity of Phobias questionnaire | 14 days/6 weeks (measured at pre-treatment, 2 weeks, and 6 weeks) | Self-report severity of phobias rating; 10 items. Scores range from "Never" to "All of the time," with a higher score indicating greater severity. | ClinicalTrials.gov |
| Secondary | Behavioral Inhibition/Behavioral Activation Scales (BIS/BAS) | 0 days (measured at pre-treatment) | Self-report behavioral inhibition/activation rating; 20 items. Scores range from "Very true for me" to "Very false for me," with a higher score indicating greater severity. | ClinicalTrials.gov |
| Secondary | Vividness of Visual Imagery Questionnaire (VVIQ) | 0 days (measured at pre-treatment) | Self-report vividness of visual imagery; 16 items. Scores range from "No image at all, you only "know" that you are thinking of the object" to "Perfectly real and vivid as real seeing," where higher scores indicate greater vividness of imagery. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| R33MH135002 | Unconscious reduction of fear through decoded neuro-reinforcement | CRASKE, MICHELLE G; MOBBS, DEAN | UNIVERSITY OF CALIFORNIA LOS ANGELES | NATIONAL INSTITUTE OF MENTAL HEALTH | 2024 to 2025 | NIH RePORTER |
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)